Investors need to pay close attention to ATR stock based on the movements in the options market lately.
AptarGroup, Inc. ( ATR ) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Stephan Tanda - President, CEO & Executive Director Gael Touya - President of Aptar Pharma Vanessa Kanu - Executive VP & CFO Conference Call Participants Daniel Rizzo - Jefferies LLC, Research Division Presentation Daniel Rizzo Jefferies LLC, Research Division Good afternoon. I am Dan Rizzo with Jefferies Equity Research.
AptarGroup's shares have dropped over 25% from summer highs due to slower growth, especially in high-margin pharma emergency solutions. ATR's valuation has compressed from 26x to 20x earnings, reflecting concerns about flat growth and a soft outlook for 2026. Pharma remains the most profitable segment, but headwinds in emergency-use delivery systems are expected to impact revenues next year.
While the top- and bottom-line numbers for AptarGroup (ATR) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AptarGroup (ATR) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $1.49 per share a year ago.
Three industrial stocks-AptarGroup, Tennant and Sealed Air-look poised to beat Q3 earnings, driven by strong end-market demand and pricing gains.
E-commerce and consumer demand will drive the Zacks Containers-Paper & Packaging industry. Stocks like BXBLY, PKG, ATR, SEE and KRT are positioned for growth.
AptarGroup (ATR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AptarGroup (ATR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AptarGroup, Inc. (NYSE:ATR ) 2025 Investor Day Call Company Participants Marry Skafidas - Senior Vice President of Investor Relations & Communications Stephan Tanda - President, CEO & Executive Director Gael Touya - President of Aptar Pharma Alex Theodorakis Marc Prieur - President of Aptar Beauty Heidi Tlili - President of Aptar Closures Vanessa Kanu - Executive VP & CFO Conference Call Participants George Staphos - BofA Securities, Research Division Ghansham Panjabi - Robert W. Baird & Co. Incorporated, Research Division Matthew Larew - William Blair & Company L.L.C.
AptarGroup, Inc. (NYSE:ATR ) Q2 2025 Earnings Conference Call August 1, 2025 9:00 AM ET Company Participants Mary Skafidas - Senior Vice President of Investor Relations & Communications Stephan B. Tanda - President, CEO & Executive Director Vanessa Kanu - Executive VP & CFO Conference Call Participants Daniel Rizzo - Jefferies LLC, Research Division Gabrial Shane Hajde - Wells Fargo Securities, LLC, Research Division George Leon Staphos - BofA Securities, Research Division Ghansham Panjabi - Robert W.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.